Canada's Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Virogin Biotech, a Vancouver, Canada-based developer of next-generation oncolytic virus (OV) therapeutics, has raised over $120 million in a Series D2 round of financing as the company looks to build its global R&D centre in China’s Shanghai city.